Erratum: Activation of the PI3K/Akt/mTOR/p70S6K Pathway is Involved in S100A4-Induced Viability and Migration in Colorectal Cancer Cells: Erratum (Int J Med Sci, (2014), 11(8), (841-849), 10.7150/ijms.8128));Activation of the PI3K/Akt/mTOR/p70S6K pathway is involved in S100A4-induced viability and migration in colorectal cancer cells

International Journal of Medical Sciences

Volumn 11, Issue 8, 2014, Pages 841-849

  Wang, Haiyan ^a   Duan, Liang ^a   Zou, Zhengyu ^b   Li, Huan ^a   Yuan, Shimei ^a   Chen, Xian ^a   Zhang, Yunyuan ^a   Li, Xueru ^a   Sun, Hui ^a   Zha, He ^a   Zhang, Yan ^a   Zhou, Lan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b The First People's Hospital of Jiulongpo of Chongqing   (China)

Author keywords

Colorectal cancer; Migration; PI3K Akt mTOR p70S6K; S100A4; Viability

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADENOVIRUS VECTOR; CALVASCULIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; UVOMORULIN; VASCULOTROPIN; CADHERIN; ENZYME INHIBITOR; MTOR PROTEIN, HUMAN; PROTEIN S 100; S100A4 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CELL MIGRATION; CELL VIABILITY; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; CELL MOTION; COLORECTAL TUMOR; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; S100 PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84902376298     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.69070     Document Type: Erratum

References (54)

1. Stein U, Schlag PM. Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res. 2007; 176: 61-80.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
3. Garrett SC, Varney KM, Weber DJ, et al. S100A4, a mediator of metastasis. J Biol Chem. 2006; 281: 677-680.
4. Takenaga K, Nakamura Y, Endo H, et al. Involvement of S100-related calcium-binding protein pEL98 (or mts1) in cell motility and tumor cell invasion. Jpn J Cancer Res. 1994; 85: 831-839.
5. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Bio-chem Cell Biol. 2001; 33: 637-668.
6. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech. 2003; 60: 540-51.
7. Kang YG, Jung CK, Lee A, et al. Prognostic significance of S100A4 mRNA and protein expression in colorectal cancer. Surg Oncol. 2012; 105: 119-24.
8. Huang LY, Xu Y, Cai GX, et al. S100A4 over-expression underlies lymph node metastasis and poor prognosis in colorectal cancer. World J Gastroen-terol. 2011; 17: 69-78.
9. Boye K, Nesland JM, Sandstad B, et al. Nuclear S100A4 is a novel prognostic marker in colorectal cancer. Eur J Cancer. 2010; 46: 2919-25.
10. Kwak JM, Lee HJ, Kim SH, et al. Expression of protein S100A4 is a predictor of recurrence in colorectal cancer. World J Gastroenterol. 2010; 16: 3897-3904.
11. Hemandas AK, Salto-Tellez M, Maricar SH, et al. Metastasis-associated protein S100A4--a potential prognostic marker for colorectal cancer. J Surg Oncol. 2006; 93: 498-503.
12. Wang YY, Ye ZY, Zhao ZS, et al. High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer. Ann Surg Oncol. 2010; 17: 89-97.
13. de Silva Rudland S, Martin L, Roshanlall C, et al. Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. Clin Cancer Res. 2006; 12: 1192-1200.
14. Ikenaga N, Ohuchida K, Mizumoto K, et al. S100A4 mRNA is a diagnostic and prognostic marker in pancreatic carcinoma. J Gastrointest Surg. 2009; 13: 1852-1858.
15. Tsuna M, Kageyama S, Fukuoka J, et al. Significance of S100A4 as a prognostic marker of lung squamous cell carcinoma. Anticancer Res. 2009; 29: 2547-2554.
16. Schneider M, Hansen JL, Sheikh SP. S100A4: a common mediator of epi-thelial-mesenchymal transition, fibrosis and regeneration in diseases. J Mol Med. 2008; 86: 507-522.
17. Boye K, Maelandsmo GM. S100A4 and metastasis: a small actor playing many roles. Am J Pathol. 2010; 176: 528-535.
18. Li W, Tan D, Zhang Z, et al. Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep. 2008; 20: 713-719.
19. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007; 12: 9-22.
20. Johnson SM, Gulhati P, Rampy BA, et al. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg. 2010; 210: 767-776.
21. Baba Y, Nosho K, Shima K, et al. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage and favorable outcome in 717 colo-rectal cancers. Cancer. 2011; 117: 1399-408.
22. Wang D, Chen J, Guo FJ, et al. Clinical significance of mTOR and p-mTOR protein expression in human colorectal carcinomas. Asian Pacific J Cancer Prev. 2011; 12: 2581-2584.
23. Nozawa H, Watanabe T, Nagawa H. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Letters. 2007; 251: 105-113.
24. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009; 361: 2449-2460.
25. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011; 6: 479-507.
26. Li ZH, Bresnick AR. The S100A4 metastasis factor regulates cellular motil-ity via a direct interaction with myosin-IIA. Cancer Res. 2006; 66: 5173-80.
27. Mathisen B, Lindstad RI, Hansen J, et al. S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis. 2003; 20: 701-711.
28. Saleem M, Kweon MH, Johnson JJ, et al. S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proc Natl Acad Sci USA. 2006; 103: 14825-14830.
29. Yammani RR, Carlson CS, Bresnick AR, et al. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: role of the receptor for advanced glycation end products. Arthritis Rheum. 2006; 54: 2901-2911.
30. Dahlmann M, Sack U, Herrmann P, et al. Systemic shRNA mediated knock down of S100A4 in colorectal cancer xenografted mice reduces metastasis formation. Oncotarget. 2012; 3: 783-797.
31. Huang L, Xu Y, Cai G, et al. Downregulation of S100A4 expression by RNA interference suppresses cell growth and invasion in human colorectal cancer cells. Oncol Rep. 2012; 27: 917-922.
32. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407: 249-257.
33. Dallas NA, Fan F, Gray MJ, et al. Functional significance of vascular en-dothelial growth factor receptors on gastrointestinal cancer cells. Cancer Metastasis Rev. 2007; 26: 433-41.
34. Garcia V, Garcia JM, Silva J, et al. Levels of VEGF-A mRNA in plasma from patients with colorectal carcinoma as possible surrogate marker of angiogen-esis. J Cancer Res Clin Oncol. 2008; 134: 1165-1171.
35. Diaz-Rubio E, Schmoll HJ. Introduction. Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer. Oncology. 2005; 69: 1-3.
36. Semov A, Moreno MJ, Onichtchenko A, et al. Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. J Biol Chem. 2005; 280: 20833-41.
37. Feng LZ, Zheng XY, Zhou LX, et al. Correlation between expression of S100A4 and VEGF-C, and lymph node metastasis and prognosis in gastric carcinoma. J Int Med Res. 2011; 39: 1333-1343.
38. Jia W, Gao XJ, Zhang ZD, et al. S100A4 silencing suppresses proliferation, angiogenesis and invasion of thyroid cancer cells through downregulation of MMP-9 and VEGF. Eur Rev Med Pharmacol Sci. 2013; 17: 1495-508.
39. Roh SA, Choi EY, Cho DH, et al. Growth and invasion of sporadic colo-rectal adenocarcinomas in terms of genetic change. J Korean Med Sci. 2010; 25: 353-360.
40. Ruan GX, Kazlauskas A. VEGF-A engages at least three tyrosine kinases to activate PI3K/Akt. Cell Cycle. 2012; 11: 2047-2048.
41. Sherbet GV, Lakshmi MS. S100A4 (MTS1) calcium binding protein in cancer growth, invasion and metastasis. Anticancer Res. 1998; 18: 2415-2421.
42. Andersen H, Mejlvang J, Mahmood S, et al. Immediate and delayed effects of E-cadherin inhibition on gene regulation and cell motility in human epi-dermoid carcinoma cells. Mol Cell Biol. 2005; 25: 9138-9150.
43. Zhang HY, Zheng XZ, Wang XH, et al. S100A4 mediated cell invasion and metastasis of esophageal squamous cell carcinoma via the regulation of MMP-2 and E-cadherin activity. Mol Biol Rep. 2012; 2039: 199-208.
44. Lee SJ, Choi SY, Kim WJ, et al. Combined aberrant expression of E-cadherin and S100A4, but not beta-catenin is associated with disease-free survival and overall survival in colorectal cancer patients. Diagn Pathol. 2013; 8: 99-121.
45. Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest. 2002; 109: 987-991.
46. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2: 489-501.
47. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signaling pathway. Nature. 2005; 436: 792.
48. Rychahou PG, Jackson LN, Silva SR, et al. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colo-rectal carcinoma. Ann Surg. 2006; 243: 833-842.
49. Ollikainen M, Gylling A, Puputti M, et al. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer. 2007; 121: 915-920.
50. Ekstrand AI, Jonsson M, Lindblom A, et al. Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam Cancer. 2010; 9: 125-9.
51. Frost P, Shi Y, Hoang B, et al. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene. 2007; 26: 2255-2262.
52. Xie SR, Wang Y, Liu CW, et al. Liquiritigenin inhibits serum-induced HIF-1alpha and VEGF expression via the AKT/mTOR-p70S6K signaling pathway in Hela cells. Phytother Res. 2012; 26: 1133-1141.
53. Zhang K, Zhang M, Zhao H, et al. S100A4 regulates motility and inva-siveness of human esophageal squamous cell carcinoma through modulating the AKT/Slug signal pathway. Dis Esophagus. 2012; 25: 731-9.
54. Lau MT, Leung PC. The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Cancer Lett. 2012; 326: 191-8.